Efficacy and safety of cefepime treatment in Chinese patients with severe bacterial infections: in comparison with ceftazidime treatment

被引:16
作者
Chang, SC
Fang, CT
Hsueh, PR
Liu, CJ
Sheng, WH
Hsieh, SM
Hung, CC
Chen, YC
机构
[1] Natl Taiwan Univ Hosp, Dept Internal Med, Infect Dis Sect, Taipei 100, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan
关键词
cefepime; ceftazidime; severe infections;
D O I
10.1016/S0924-8579(98)00040-5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
An open label, randomized comparative study was conducted to evaluate the safety and efficacy of cefepime, in comparison with ceftazidime, in the treatment of adult hospitalized Chinese patients with severe bacterial infections. Forty patients with severe infections including septicemia, urinary tract infection and bacterial pneumonia were randomly assigned to receive treatment with cefepime (2 g intravenously every 12 h) or ceftazidime (2 g intravenously every 8 h). The cefepime group (20 evaluable patients) and ceftazidime group (16 evaluable patients) were comparable with respect to age, sex, underlying diseases and distribution of infection type. In both groups urinary tract infection was the most common type of infection and Escherichia coli was the most common etiologic microorganism. The rates of satisfactory clinical response were similar in the cefepime and ceftazidime groups (95 versus 93.7%; 95% confidence interval: - 0.14 similar to 0.17, P = 0.87). The bacteriological response rates of the cefepime and ceftazidime groups did not differ significantly (88.9 versus 85.7%; 95% confidence interval: - 0.30 similar to 0.36, P = 0.85). Both cefepime and ceftazidime were well tolerated, with similar incidence of side effects. The results of this study suggest that cefepime is as safe and effective as ceftazidime for the treatment of serious infections in adult hospitalized Chinese patients. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:245 / 248
页数:4
相关论文
共 16 条
[1]   IN-VITRO ACTIVITIES OF CEFEPIME AGAINST ENTEROBACTER-CLOACAE, SERRATIA-MARCESCENS, PSEUDOMONAS-AERUGINOSA AND OTHER AEROBIC GRAM-NEGATIVE BACILLI [J].
CHONG, YS ;
LEE, KW ;
KWON, OH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 :21-29
[2]   THE USE OF CEFEPIME (BMY-28142) TO TREAT RESPIRATORY-INFECTIONS [J].
CLYNES, N ;
SCULLY, BE ;
NEU, HC .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1989, 12 (03) :257-260
[3]   IN-VITRO ANTIBACTERIAL ACTIVITY OF CEFEPIME - A MULTICENTER STUDY [J].
DUVAL, J ;
SOUSSY, CJ ;
ACAR, JF ;
BERGOGNEBEREZIN, E ;
CLUZEL, R ;
THABAUT, A ;
COURVALIN, P ;
GRES, JJ ;
ROLLIN, C .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 :55-61
[4]   A RANDOMIZED TRIAL OF CEFEPIME (BMY-28142) AND CEFTAZIDIME FOR THE TREATMENT OF PNEUMONIA [J].
EDELSTEIN, H ;
CHIRURGI, V ;
OSTER, S ;
KARP, R ;
CASSANO, K ;
AIKEN, S ;
MCCABE, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 28 (04) :569-575
[5]  
Fekete Thomas, 1996, American Journal of Medicine, V100, p20S, DOI 10.1016/S0002-9343(96)00104-0
[6]   ACTIVITY OF CEFEPIME AGAINST CEFTAZIDIME-RESISTANT AND CEFOTAXIME-RESISTANT GRAM-NEGATIVE BACTERIA AND ITS RELATIONSHIP TO BETA-LACTAMASE LEVELS [J].
FUNGTOMC, J ;
DOUGHERTY, TJ ;
DEORIO, FJ ;
SIMICHJACOBSON, V ;
KESSLER, RE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (04) :498-502
[7]   LOW-DOSAGE CEFEPIME AS TREATMENT FOR SERIOUS BACTERIAL-INFECTIONS [J].
GIAMARELLOU, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 :123-132
[8]   CEFEPIME - OVERVIEW OF ACTIVITY IN-VITRO AND IN-VIVO [J].
GRASSI, GG ;
GRASSI, C .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 :87-94
[9]   INTERNATIONAL COMPARATIVE-STUDY OF CEFEPIME AND CEFTAZIDIME IN THE TREATMENT OF SERIOUS BACTERIAL-INFECTIONS [J].
HOEPELMAN, AIM ;
KIEFT, H ;
AOUN, M ;
KOSMIDIS, J ;
STRAND, T ;
VERHOEF, J ;
GILLESPIE, SH ;
RIDDELL, J ;
VARGHESE, G ;
MEUNIER, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 :175-186
[10]  
Holloway William J., 1996, American Journal of Medicine, V100, p52S, DOI 10.1016/S0002-9343(96)00108-8